Ultragenyx Pharmaceutical Inc.

What they do

Ultragenyx develops and commercializes therapies for serious rare and ultra-rare genetic diseases. Its approved products are Crysvita (XLH and TIO), Mepsevii (MPS VII), Dojolvi (LC-FAOD), and Evkeeza (HoFH). The pipeline spans biologics, small molecules, AAV gene therapies, and nucleic acid candidates, including DTX401, UX111, GTX-102, and UX701.

Revenue drivers

• Crysvita — The largest product, generating $156 million in Q2 2026 and full-year guidance of $500–520 million; also subject to royalty sales to Royalty Pharma and OMERS.
• Dojolvi — Generated $27 million in Q2 2026; full-year guidance of $100–110 million; launched in Japan in 2026.
• Evkeeza — Generated $21 million in Q2 2026, driven by demand from new country launches and early access.
• Mepsevii — Generated $10 million in Q2 2026; the smallest commercial product.

Recent performance

Total revenue in Q2 2026 was $214 million, the highest quarterly revenue in company history, with full-year 2026 guidance reaffirmed at $730–760 million. The company has incurred net losses every year since inception, with a 2025 net loss of $575 million. Cash and equivalents were $125 million as of June 30, 2026, down from $737 million in available cash at year-end 2025. Operating cash flow remained negative at $-466 million in 2025.

Strategy

Management is focused on launching two gene therapy products (DTX401 and UX111) and preparing for a pivotal GTX-102 readout in Angelman syndrome. The company is also advancing earlier-stage programs such as UX016 and UX701 and reaffirmed profitability guidance for 2027. After the UX143 Phase 3 failure, Ultragenyx initiated significant expense reductions and is prioritizing pipeline assets. It may seek additional capital through royalty sales or partnerships, as it has done with Royalty Pharma and OMERS, and with Daiichi Sankyo.

Risks

• History of operating losses — The company has never been profitable and expects net losses to continue in the near term, with a cumulative net loss of $575 million in 2025.
• Clinical development failures — Late-stage trials can fail despite promising earlier data, as seen with UX143's Phase 3 studies missing primary endpoints in December 2025, leading to expense reductions and pipeline reassessment.
• Need for additional capital — Cash and equivalents were only $125 million at June 30, 2026, and the company may need to raise funds through dilutive equity or debt, or by selling future royalties.
• Regulatory and launch execution risk — Two gene therapy BLAs are under FDA review with PDUFA dates in 2026, and success depends on timely approvals and successful commercial launches.

Outlook

Management reaffirmed 2026 total revenue guidance of $730–760 million and expects combined R&D and SG&A expenses to be flat to slightly down versus 2025. Second-half 2026 catalysts include PDUFA decisions for DTX401 (August 23, 2026) and UX111 (September 19, 2026), and a pivotal data readout from GTX-102's Phase 3 Aspire study. The company remains on track to reach profitability in 2027.